Biopharmaceutical company focused on developing therapies for rare pulmonary diseases.
Insmed Incorporated, a prominent biopharmaceutical company, specializes in the development and commercialization of innovative therapies tailored for patients grappling with severe and uncommon diseases. One of its notable offerings includes ARIKAYCE, which forms part of a comprehensive antibacterial drug regimen for adult patients combating Mycobacterium avium complex lung disease. Beyond this, Insmed is advancing Brensocatib, an oral dipeptidyl peptidase 1 inhibitor designed to address bronchiectasis and other conditions driven by neutrophil-mediated inflammation.
The company's pipeline also features Treprostinil Palmitil Inhalation Powder, an inhalable formulation of treprostinil palmitil, aimed at treating pulmonary arterial hypertension and other rare pulmonary disorders. Founded in 1988 and headquartered in Bridgewater, New Jersey, Insmed has established itself as a leader in the biopharmaceutical sector, leveraging its decades of experience and commitment to scientific innovation to improve patient outcomes globally.
Insmed is dedicated to pioneering treatments that target diseases often overlooked by traditional pharmaceutical research, reflecting its mission to address unmet medical needs in underserved patient populations. With a focus on rigorous scientific research and development, the company continues to expand its portfolio and explore new therapeutic avenues aimed at transforming the lives of those affected by rare and challenging medical conditions.
Driven by a patient-centric approach, Insmed remains steadfast in its pursuit of advancing therapies that not only treat symptoms but also enhance quality of life. Through strategic partnerships and collaborations, the company endeavors to accelerate the development and accessibility of breakthrough treatments, reinforcing its commitment to making a meaningful impact in global healthcare.